Current concepts and novel targets in advanced pancreatic cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer remains one of the most aggressive tumours with a 5-year survival rate of less than 5%. The dismal prognosis of this tumour entity that is associated with a high degree of drug resistance has not changed over the past decades. Since 1997, gemcitabine-based regimens have been the therapy of choice for advanced pancreatic cancer. Recently, however, new combination chemotherapy regimens achieved a significant survival benefit compared to gemcitabine-based therapies. In addition, novel approaches to improve drug delivery are currently being developed, and new drugs targeting signalling pathways both within the tumour cells and the tumour microenvironment are undergoing preclinical and clinical validation. Furthermore, efforts are being made to identify predictive markers for individualised treatment approaches based on molecular tumour characteristics. This review provides an overview on current and emerging concepts as well as novel targets for systemic treatment of advanced pancreatic cancer. Combination therapies incorporating drugs directed against these new targets may open new avenues for improving the efficacy of current treatment approaches and overcoming the devastating prognosis of pancreatic cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 1×
“8 months in the control arm using gemcitabine alone.(16) As expected, the side effects of this new combination regimen were significant, including a grade 3 and 4 neutropenia rate of 45.”
MethodMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9526-z · Cited by 103
Olson, P., & Hanahan, D. (2009) · Science · doi:10.1126/science.1175940 · Cited by 62 · cited 1×
“Based on recent preclinical data in mouse models that will be discussed below in detail, it has been hypothesised that currently available cytotoxic drugs can not access tumour cells at an effective concentration due to the extensive hypovascular stroma reaction that acts as a fence around tumour cells protecting them…”
Background
Cited by
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Self-citationCalabretta, S., Bielli, P., Passacantilli, I., Pilozzi, E., Fendrich, V, Capurso, G., Fave, G. D., & Sette, C. (2016) · Oncogene · doi:10.1038/onc.2015.270 · Cited by 249
“Nevertheless, relapse always occurs with more aggressive features and insensitivity to chemotherapy, contributing to high lethality (2,3).”
Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142
“Even the patients obtained radical resection and adjuvant chemotherapy, the 5-year survival rate is between 15 % and 25 % [2].”
BackgroundThe Impact of Neural Invasion Severity in Gastrointestinal Malignancies: A Clinicopathological Study
Liebl, F., Demir, I. E., Mayer, K., Schuster, T., D'Haese, J. G., Becker, K., Langer, R., Bergmann, F., Wang, K., Rosenberg, R., et al. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000968 · Cited by 131
Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., Tian, R., Shi, C., Xu, M., Peng, F., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.026 · Cited by 116
Metadata
- Authors
- Michl, P., & Gress, T. M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2012-10-30
- Volume
- 62
- Issue
- 2
- Pages
- 317-326
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2163968551
- Cited by
- 152
- References
- 9
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current concepts and novel targets in advanced pancreatic cancer. https://app.cochat.ai/papers/10.1136/gutjnl-2012-303588
- The paper
- Michl, P., & Gress, T. M. (2013). Current concepts and novel targets in advanced pancreatic cancer. Gut. https://doi.org/10.1136/gutjnl-2012-303588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.